skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

About Zachary


+3 year(s) experience

Oncology Analyst Zachary McLellan specializes in the various subtypes of breast and ovarian cancers. He focuses on current market developments and treatment trends, as well as indication-specific market and drug forecasting.

Zachary McLellan is an Oncology analyst specializing in the coverage of prostate, ovarian, and breast cancers. He focuses on current market developments and treatment trends, as well as indication-specific market and drug forecasting. As an Analyst, Zachary shares his insights through individualized reports, direct client interactions, and Datamonitor Healthcare's online platform. He has also represented Datamonitor Healthcare at the 2016 ASCO conference. His conference coverage included timely analysis through bespoke reports and a live webinar that was attended by clients, prospective clients, investors and other interested parties.


Zachary joined Informa in June 2015 while completing an MSc in Biotechnology and Entrepreneurship from New York University. Prior to Informa, he worked as a chemist.


Analyst Articles

Articles by Zachary

  • Datamonitor Healthcare

    Datamonitor Healthcare Podcast 16 February 2018

    By Zachary McLellan 19 Feb 2018

    Zach McLellan and Jack Allen discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including a recap of the 2018 BIO CEO conference, Phase IIb results of aramchol in HIV-lipodystrophy NAFLD or NASH patients, and the approval of Ereleada (apalutamide) in non-metastatic castration-resistant prostate cancer.

    Topic Business strategies BioPharmaceutical

  • Datamonitor Healthcare

    The APHINITY trial update signals strong growth for Perjeta and for Roche’s overall HER2+ breast cancer portfolio

    By Zachary McLellan 10 Mar 2017

    Perjeta (pertuzumab; Genentech/Roche/Chugai) is poised for a label expansion into the early-stage human epidermal growth factor receptor 2-positive (HER2+) breast cancer setting after a positive readout from the Phase III APHINITY trial ( identifier: NCT01358877). In the trial, the combination of Perjeta, Herceptin (trastuzumab; Roche/Chugai), and chemotherapy showed a statistically significant improvement in invasive disease-free survival (iDFS) over Herceptin and chemotherapy alone for the adjuvant treatment of early-stage HER2+ breast cancer patients (Roche press release, 2017). This significant improvement in survival will likely mean the Perjeta/Herceptin/chemotherapy combination will be considered the new standard of care for early-stage HER2+ breast cancer patients receiving surgery

    Topic Cancer Clinical trials

  • Datamonitor Healthcare

    Celgene opts in on Juno’s early-phase CAR-T therapies for $1bn upfront

    By Zachary McLellan 02 Jul 2015

    On 29 June 2015, Celgene and Juno Therapeutics announced a global collaboration for the development and commercialization of chimeric antigen receptor T cells (CAR-T) and T-cell receptor

    Topic Cell and gene therapy